Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a biopharmaceutical company based in China, has announced that it has received approval from the National Medical Products Administration (NMPA) to advance its drug candidate, GNC-077, into clinical trials for the treatment of advanced solid tumors. GNC-077 is a multi-specific antibody developed on the GNC platform, a proprietary research and development arm of Biokin focused on multi-specific antibody therapies. This innovative treatment combines antibody domains that target T cell CD3 and T cell immune checkpoints with domains that target tumor antigens. GNC-077 is designed to effectively activate, differentiate, and proliferate T cells, enabling them to specifically target and kill tumor cells that express the relevant antigens. Preliminary in vivo studies have demonstrated the drug candidate’s potent anti-tumor effects across a range of solid tumor types.- Flcube.com
Biokin Pharmaceutical Cancer Clinical trial approval / initiation Multi-specific antibodies SHA: 688506
Recent news:
-
Sino Biopharmaceutical Submits NDA for Anlotinib and Penpulimab Combo in HCC to NMPA -
Sihuan Pharmaceutical's Huisheng Pharm Strikes Exclusive Deal for Semaglutide Biosimilar in China -
Innovent Biologics' IBI354 Earns Breakthrough Therapy Designation for Ovarian Cancer Treatment -
CDE Includes Double-Crane's Hydroxocobalamine and Sanofi Genzyme's Fitusiran in Rare Disease Care Plan -
Apeiron Therapeutics Initiates Phase Ia/B Study for GTA182 in Solid Tumors with MTAP Deficiency
